secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2024-06-07T23:59:59+00:00
Accession:  0001798749-24-000033
Event type: other
Sentiment:  neutral
Materiality: 0.05
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Aerovate Therapeutics stockholders elect directors and ratify KPMG as auditor at 2024 annual meeting
--------------------------------------------------------------------------------

- Stockholders elected David Grayzel, M.D. and Maha Katabi, Ph.D. as Class III directors with 24.4M and 25.9M votes for, respectively.
- Ratification of KPMG LLP as independent auditor for FY 2024 was approved with 28,074,033 votes for, 511 against, 105 abstain.
- The meeting was held on June 5, 2024; 28,737,381 shares were outstanding and entitled to vote as of April 12, 2024 record date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000179874924000033/0001798749-24-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000179874924000033/tmb-20240605x8k.htm
  HTML page:      https://secwatch.observer/filing/0001798749-24-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer